Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose We investigated the clinical relevance and spectrum of BRCA1/2mutations in Korean ovarian cancer (KoOC) patients. Materials and Methods Two hundred seventy-nine KoOC patients were enrolled from three university hospitals between 2012 and 2017. Their peripheral blood samples were obtained for BRCA1/2 mutation analysis by direct sequencing. Clinicopathological characteristics were retrospectively reviewed, and spectrum analyses of BRCA1/2mutation were assessed by systematic literature review. Results Frequency of BRCA1/2mutations was 16.5% in KoOC patients. BRCA1/2mutations were significantly associated with family history of breast/ovarian cancer (p < 0.001), serous histology (p=0.044), and advanced International Federation of Gynecology and Obstetrics (FIGO) stage (III/IV, p=0.018) but not with early age-of-onset (age < 50, p=0.729). Literature review of BRCA1/2mutations in KoOC patients found 111 (55 distinct) mutations with high proportion of Korean-specific mutations (24/55, 43.6%). Comparing the spectrum of BRCA1/2 mutation between KoOC and Korean breast cancer (KoBC) patients, the ratio of BRCA1-to-BRCA2mutations was different, with BRCA1 (78.4%) being predominant in KoOC and BRCA2 in KoBC (59.2%). The most common mutation also differed between the two (c.3627insA of BRCA1 in KoOC and c.7480C>T of BRCA2 in KoBC). Conclusion The clinical relevance of BRCA1/2 mutations in KoOC patients was confirmed but that of early age-of-onset was not. Possible inconsistency in the ratio of BRCA1-to-BRCA2mutations and the most common mutation between KoOC and KoBC may probably suggest presence of mutation sequence-associated penetrance tendency in hereditary Korean breast and ovarian cancer. These data may provide insights for optimal genetic counseling and prophylactic treatment for at-risk relatives of KoOC patients.
Abstract
Purpose We investigated the clinical relevance and spectrum of BRCA1/2mutations in Korean ovarian cancer (KoOC) patients. Materials and Methods Two hundred seventy-nine KoOC patients were enrolled from three university hospitals between 2012 and 2017. Their peripheral blood samples were obtained for BRCA1/2 mutation analysis by direct sequencing. Clinicopathological characteristics were retrospectively reviewed, and spectrum analyses of BRCA1/2mutation were assessed by systematic literature review. Results Frequency of BRCA1/2mutations was 16.5% in KoOC patients. BRCA1/2mutations were significantly associated with family history of breast/ovarian cancer (p < 0.001), serous histology (p=0.044), and advanced International Federation of Gynecology and Obstetrics (FIGO) stage (III/IV, p=0.018) but not with early age-of-onset (age < 50, p=0.729). Literature review of BRCA1/2mutations in KoOC patients found 111 (55 distinct) mutations with high proportion of Korean-specific mutations (24/55, 43.6%). Comparing the spectrum of BRCA1/2 mutation between KoOC and Korean breast cancer (KoBC) patients, the ratio of BRCA1-to-BRCA2mutations was different, with BRCA1 (78.4%) being predominant in KoOC and BRCA2 in KoBC (59.2%). The most common mutation also differed between the two (c.3627insA of BRCA1 in KoOC and c.7480C>T of BRCA2 in KoBC). Conclusion The clinical relevance of BRCA1/2 mutations in KoOC patients was confirmed but that of early age-of-onset was not. Possible inconsistency in the ratio of BRCA1-to-BRCA2mutations and the most common mutation between KoOC and KoBC may probably suggest presence of mutation sequence-associated penetrance tendency in hereditary Korean breast and ovarian cancer. These data may provide insights for optimal genetic counseling and prophylactic treatment for at-risk relatives of KoOC patients.
참고문헌 (25)
- Banerjee S, "New strategies in the treatment of ovarian cancer : current clinical perspectives and future potential", Clin Cancer Res, 19, pp.961~968 (2013)
- 김세익, "Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012", Journal of Gynecologic Oncology, 27(1), pp.1~10 (2016), 대한부인종양학회
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014", Cancer Research and Treatment, 49(2), pp.292~305 (2017), 대한암학회
- Lakhani SR, "Pathology of ovarian cancers in BRCA1 and BRCA2 carriers", Clin Cancer Res, 10, pp.2473~2481 (2004)
- Tan DS, ""BRCAness"syndrome in ovarian cancer : a casecontrol study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1and BRCA2 mutations", J Clin Oncol, 26, pp.5530~5536 (2008)
- Alsop K, "BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer : a report from the Australian Ovarian Cancer Study Group", J Clin Oncol, 30, pp.2654~2663 (2012)
- Fong PC, "Poly(ADP)-ribose polymerase inhibition : frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval", J Clin Oncol, 28, pp.2512~2519 (2010)
- Audeh MW, "Oral poly(ADP-ribose)polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer : a proof-of-concept trial", Lancet, 376, pp.245~251 (2010)
- Lim MC, "BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients", J Cancer Res Clin Oncol, 135, pp.1593~1599 (2009)
- Choi MC, "Germline mutations of BRCA1 and BRCA2 in Korean ovarian cancer patients : finding founder mutations", Int J Gynecol Cancer, 25, pp.1386~1391 (2015)
- 어경진, "Comparison of Clinical Outcomes of BRCA1", 2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients, 2017, pp.49(2), 408~415[DOI]
- Kim H, "Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer", Breast Cancer Res Treat, 134, pp.1315~1326 (2012)
- Kang E, "The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population : recent update of the Korean Hereditary Breast Cancer(KOHBRA)study", Breast Cancer Res Treat, 151, pp.157~168 (2015)
- Pal T, "BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases", Cancer, 104, pp.2807~2816 (2005)
- Risch HA, "Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances : a kin-cohort study in Ontario, Canada", J Natl Cancer Inst, 98, pp.1694~1706 (2006)
- Hasmad HN, "Evaluation of germline BRCA1 and BRCA2mutations in a multi-ethnic Asian cohort of ovarian cancer patients", Gynecol Oncol, 141, pp.318~322 (2016)
- Sakamoto I, "BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer", Cancer, 122, pp.84~90 (2016)
- Shi T, "BRCA1 and BRCA2 mutations in ovarian cancer patients from China : ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer", Int J Cancer, 140, pp.2051~2059 (2017)
- Boyd J, "Clinicopathologic features of BRCA-linked and sporadic ovarian cancer", JAMA, 283, pp.2260~2265 (2000)
- Soegaard M, "BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark", Clin Cancer Res, 14, pp.3761~3767 (2008)
- Seong MW, "Comprehensive mutational analysis of BRCA1", BRCA2 for Korean breast cancer patients : evidence of a founder mutation, 2009, pp.76, 152~160
- Rebbeck TR, "Association of type and location of BRCA1and BRCA2 mutations with risk of breast and ovarian cancer", JAMA, 313, pp.1347~1361 (2015)
- Friedman LS, "Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families", Am J Hum Genet, 57, pp.1284~1297 (1995)
- Tonin P, "Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families", Nat Med, 2, pp.1179~1183 (1996)
- Neuhausen S, "Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer", Nat Genet, 13, pp.126~128 (1996)